In the future, if it is determined that somatostatin or its analogues can safely and consistently help avoid SFSS/PHLF and associated morbidity and mortality, these agents may find greater application in and help expand the clinical indication of major liver resection and partial liver transplantation for the treatment of liver tumors and end-stage liver disease. Here, SST is linked to End Stage Liver Disease.